MARKET

BDSI

BDSI

BDSI
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.142
-0.078
-1.86%
Opening 13:27 03/03 EST
OPEN
4.230
PREV CLOSE
4.220
HIGH
4.230
LOW
4.100
VOLUME
439.34K
TURNOVER
--
52 WEEK HIGH
5.45
52 WEEK LOW
2.850
MARKET CAP
418.77M
P/E (TTM)
30.01
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO
Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO
CNW Group · 1d ago
Opioid Use Disorder Market Size, Share, Growth, Industry Analysis, Opportunities and Forecast 2019-2025
Mar 01, 2021 (Market Insight Reports) -- The global opioid use disorder market is estimated to witness significant growth during the forecast period...
Market Insight Reports · 2d ago
NIU, SPPI, BDSI and SVC among after-hours movers
Gainers: [[SIOX]] +12.1%. [[OPTN]] +7.2%. [[BDSI]] +5.7%. [[SSP]] +4.9%. [[SPPI]] +4.9%.Losers: [[PCTI]] -6.5%. [[SVC]] -5.4%. [[GNFT]] -4.2%. [[NIU]] -3.4% [[CATB]] -2%.
Seekingalpha · 4d ago
Opioid Withdrawal Management Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 17, 2021 (Market Insight Reports) -- The report for Opioid Withdrawal Management offers an assiduous analysis of contemporary market trends, driving...
Market Insight Reports · 02/17 13:38
BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full year 2020 ...
GlobeNewswire · 02/17 13:00
2 Health Care Stocks Under $5 to Buy Now: BioDelivery Sciences and Global Cord Blood
StockNews.com · 02/17 11:59
How to trade Biodelivery Sciences $BDSI With Risk Controls
Stock Traders Daily · 02/15 13:18
BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice President
Brings Track Record of Success to Expanded RoleRALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions...
GlobeNewswire · 02/11 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BDSI. Analyze the recent business situations of BDSI through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BDSI stock price target is 8.00 with a high estimate of 9.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 243
Institutional Holdings: 79.64M
% Owned: 78.76%
Shares Outstanding: 101.11M
TypeInstitutionsShares
Increased
54
8.97M
New
42
-4.05M
Decreased
41
4.81M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.91%
Pharmaceuticals & Medical Research
-1.25%
Key Executives
Chairman/Independent Director
Peter Greenleaf
Chairman/Director
Francis O'Donnell
President
Scott Plesha
Chief Executive Officer
Jeffrey Bailey
Chief Financial Officer
Terry Coelho
Vice Chairman/Director
Mark Sirgo
Chief Financial Officer/Treasurer
Mary Coelho
Senior Vice President
Joseph Lockhart
Senior Vice President
Kevin Ostrander
Chief Compliance Officer/General Counsel/Secretary
James Vollins
Other
Thomas Smith
Independent Director
Todd Davis
Independent Director
Kevin Kotler
Independent Director
Vanila Singh
Director
W. Mark Watson
Independent Director
William Watson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About BDSI
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Webull offers kinds of BioDelivery Sciences International, Inc. stock information, including NASDAQ:BDSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDSI stock methods without spending real money on the virtual paper trading platform.